ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1679

Clinical Implications Of Antiphospholipid Antibodies In Takayasu’s Arteritis

Natasha Jordan1, Holy Bezanahary1 and David P. D'Cruz2, 1Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, 2Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: antiphospholipid and vasculitis, Takayasu.s arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Takayasu’s arteritis (TA) is a granulomatous inflammation of unknown origin involving the aorta and its major branches. Association and implication of antiphospholipid antibodies (aPL) in the TA disease process remain controversial. The aim of this research was to ascertain if aPL positivity or the presence of Antiphospholipid Syndrome (APS) were predictive of a worse clinical outcome in TA.

Methods:

Clinical data was retrospectively collected on 22 TA patients over an 11 year period (2001-2012). All patients fulfilled the ACR criteria for TA. Patients were categorised into 2 groups: a diagnosis of TA alone or a diagnosis of TA with either persistently positive anticardiolipin antibodies and/or lupus anticoagulant or a concurrent clinical diagnosis of APS. Those with APS met the Sapporo classification criteria.

Screening for lupus anticoagulant was performed using the dRVVT (dilute Russell’s viper venom time) assay in accordance with standard methods. Confirmatory tests used a combination of mixing studies and correction with phospholipid. IgG and IgM anticardiolipin antibodies were measured using a standardized ELISA. Since anti-beta-2-glycoprotein-1 antibodies were not routinely measured clinically during the early stages of the study, they were not included in the analysis.

Adverse clinical outcomes included cerebrovascular accident (CVA),transient ischaemic attack (TIA), loss of vision, vascular lesions (carotid, femoral, renal coronary or other vessels) requiring stenting, angioplasty or other surgical intervention, aortic valve replacement, end-stage renal failure or death.

Results:

59% of patients had TA without aPL (n=13) and 41% had TA with a persistently positive aPL or a concurrent diagnosis of APS (n=9). Overall 7 significant vascular complications occurred in TA patients without aPL including 1 CVA, 1 TIA, 1 carotid endarterectomy and 4 angioplasty/stenting procedures.  8 such events occurred in TA patients with aPL/APS including 2 CVAs, 1 carotid endarterectomy, 1 aortic valve replacement and 4 angioplasty/stenting procedures. No patients developed end-stage renal failure or loss of vision. There were no deaths in this study cohort.

Conclusion:

Persistently positive aPL and APS are present in a significant proportion of TA patients. Our concern was that these individuals may have a worse clinical outcome in terms of vascular complications. This study has shown that this is not the case and that vascular complications and need for intervention are equal in TA patients regardless of aPL positivity.


Disclosure:

N. Jordan,
None;

H. Bezanahary,
None;

D. P. D’Cruz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-implications-of-antiphospholipid-antibodies-in-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology